Navigation Links
Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union
Date:12/16/2009

HAMBURG, Germany, December 16 /PRNewswire/ -- Eppendorf has initiated an import ban for Nanosphere, Inc.'s Verigene(R) and Verigene(R) SP systems for infringement of European patent EP 1 179 180 B2, titled "Method for the identification and/or the quantification of a target compound". The import ban covers any and all imports of the respective products into any country of the European Union. Customs authorities are required to confiscate any violating products.

The patent covers Eppendorf's Silverquant(R) microarray technology, offered in Eppendorf's Silverquant scanner and Silverquant detection kit used e.g. for Eppendorf's own microarrays. The technology is also licensed to two companies for commercialization with their microarrays.

In addition, Eppendorf has successfully initiated an import ban for the Verigene(R) kits based on the German utility model DE 20023342U1, also covering Eppendorf's Silverquant products. This ban prohibits imports into Germany either from outside the EU or from within the EU.

"Considering Nanosphere's announcement of having received the CE mark for the Verigene(R) system, Eppendorf has taken these steps to prevent the introduction of these products that are not licensed to use our patented technology into the European Union", commented Sven Bulow, Managing Director of Eppendorf Biochip Systems GmbH.

Eppendorf AG was founded in Hamburg in 1945 and has more than 2,450 employees worldwide. The company has subsidiaries in 20 countries and is represented in all other markets by distributors.

In fiscal 2008, the company's sales revenues amounted to EUR 410 million with earnings before interest and taxes (EBIT) of EUR 71.9 million.

    Contact:
    Dr. Sven Buelow
    Managing Director
    Eppendorf Biochip Systems GmbH
    Tel: +49-40-538-01-500
    Fax: +49-40-538-01-140
    buelow.s@eppendorf.de


SOURCE Eppendorf AG


'/>"/>
SOURCE Eppendorf AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New Brunswick Scientific Completes Merger Transaction with Eppendorf
2. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
3. Life on Mars pregnancy test successfully launched
4. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
5. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
6. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
7. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
8. TopoTarget Successfully Buys Back Full Control of Belinostat
9. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
10. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
11. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017 The global biotechnology services outsourcing ... by 2025, according to a new report by ... adaptive of the function of outsourcing certain clinical ... the services outsourced, clinical trial management and contract ... Johnson was the first pharmaceutical company to outsource ...
(Date:1/19/2017)... 2017 BD (Becton, Dickinson and Company) (NYSE: ... will host a live webcast of its Annual Meeting of Shareholders ... The webcast can be accessed from the BD corporate website ... January 31, 2017. ... About BD BD is a global medical technology company ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017   Boston ... novel compounds designed to target cancer stemness pathways, will ... investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers ... Francisco . Napabucasin is an ... by targeting STAT3. i Cancer stem cells (CSCs) ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive ... 2017 in its continued commitment to the advancement of the clinical trials segment. ... issues related to clinical trial planning and management. , As executive talent ...
Breaking Biology Technology:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):